The Senate Judiciary Committee has advanced bills addressing prescription drug pricing and patent reform, which have bipartisan support. There is hope for change, but past failures and industry resistance may pose challenges. The bills aim to increase competition and lower drug prices by addressing tactics used to extend patent monopolies.